Work

Mp64-05 Trends in Incidence and Survival Among Men With Metastatic Prostate Cancer: Seer Analysis 2004-2015

Year: 2020

Type: article

Abstract: You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP64)1 Apr 2020MP64-05 TRENDS IN INCIDENCE AND SURVIVAL AMONG MEN WITH METASTATIC PROSTATE CANCER: SEER ANALYSIS 2004-2015 Rehana Rasul, Anne Golden, and Michael Feuerstein* Rehana RasulRehana Rasul More articles by this author , Anne GoldenAnne Golden More articles by this author , and Michael Feuerstein*Michael Feuerstein* More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000939.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Since docetaxel was approved in 2004, several new drugs have been approved demonstrating efficacy and improved survival for metastatic prostate cancer patients. In the past decade prostate cancer screening has decreased, in part due to the USPSTF recommendation in 2012. This study evaluated the impact of these developments on population trends in metastatic prostate cancer incidence and survival. METHODS: Men ≥18 years diagnosed with de novo stage M1 prostate cancer from 2004-2015 were identified from SEER 18 Registries. M1 was classified as non-regional lymph nodes (M1a), bone metastasis with or without lymph nodes (M1b) and distant metastatic disease (M1c). Age-adjusted incidence rates per 100,000 were calculated. Unadjusted 2-year overall and prostate cancer mortality rates by year of diagnosis were calculated using the Kaplan Meier method. RESULTS: We identified 34,888 men with M1 prostate cancer with median age of 72 years. From 2004-2015, there was a slight increase in de novo M1 disease from 10.2 per 100,000 to 12.1 per 100,000 (Figure). M1b prostate cancer rates increased, while M1a and M1c rates remained stable. 2-year overall mortality for M1 disease decreased from 0.50 (±0.01) to 0.46 (±0.01) from 2004-2014, while 2-year prostate cancer mortality decreased from 0.40 (±0.01) to 0.37 (±0.01). CONCLUSIONS: As might be expected from decreased screening, there was an increase in diagnosis of de novo metastatic prostate cancer from 2004-2015. Population data also demonstrated a modest improvement in survival from 2004-2015. The survival trend may be less pronounced than expected due to decreased screening and later diffusion of effective treatments. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e964-e964 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rehana Rasul More articles by this author Anne Golden More articles by this author Michael Feuerstein* More articles by this author Expand All Advertisement PDF downloadLoading ...

Source: The Journal of Urology

DOI: 10.1097/ju.0000000000000939.05

Authors: Rehana Rasul, Anne Golden, Michael Feuerstein*

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institute for Health and Care Research, Department of Health and Social Care, University College London, Medical Research Council

Awards: Methods for analysing national routine electronic records for cancer patients in England, Multimodal treatment for patients with prostate cancer: a national study using existing electronic data.